

Freedom of Information Request: Our Reference CTMUHB_114_26

You asked:

Q1a – How many patients were treated with the following drugs from the following departments (for any disease) from the start of October 2025 to the end of December 2025?

Please use the latest available 3 months if October to December is not available and specify which 3 months have been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept			
Etrasimod			
Filgotinib			
Golimumab			
Guselkumab			
Infliximab (Biosimilars)			
Infliximab (Remicade)			
Ixekizumab			
Mirikizumab			
Ozanimod			
Risankizumab			
Secukinumab			
Tildrakizumab			
Tofacitinib			
Upadacitinib			
Ustekinumab			
Vedolizumab			

Our response:

Please find below a table populated with the information Medicines Management is able to provide at present in relation to the medicines list above. The period the data covers refers to 1st October 2025 to 31st December 25, as requested.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab	85	227	546
Apremilast	16	0	5
Bimekizumab	17	0	49
Brodalumab	**	0	0
Certolizumab Pegol	6	**	64
Deucravacitinib	23	0	0
Etanercept	**	0	282
Etrasimod	0	0	0
Filgotinib	0	0	16
Golimumab	0	0	55
Guselkumab	63	0	**
Infliximab (Biosimilars)	**	258	24
Infliximab (Remicade)	0	**	0
Ixekizumab	17	0	26
Mirikizumab	0	0	0
Ozanimod	0	0	0
Risankizumab	64	43	0
Secukinumab	10	0	96
Tildrakizumab	15	0	0
Tofacitinib	**	0	9
Upadacitinib	14	69	53
Ustekinumab	49	200	23
Vedolizumab	0	0	237